Compositions and methods for treating cancer

Patent metadata

Field	Value
Publication number	US-10023588-B2
Application number	US-201514934184-A
Country	US
Kind code	B2
Filing date	Nov 6, 2015
Priority date	Apr 10, 2012
Publication date	Jul 17, 2018
Grant date	Jul 17, 2018

Abstract

K-Ras is the most frequently mutated oncogene in human cancer. Disclosed herein are compositions and methods for modulating K-Ras and treating cancer.

First claim

What is claimed is:

1. A compound of Formula:

or a pharmaceutically acceptable salt thereof, wherein:
e5 is an integer from 0 to 5;
X′ is —O—, —NH—, or —S—;
R 2A and R 2B are independently hydrogen or unsubstituted alkyl;
R 3 is independently oxo, halogen, —CX 3 , —CN, SO 2 Cl, —SO nR 10 , —SO v NR 7 R 8 , —NHNH 2 , —ONR 7 R 8 , —NHC═(O)NHNH 2 , —NHC═(O)NR 7 R 8 , —N(O) m , —NR 7 R 8 , —C(O)R 9 , —C(O)—OR 9 , —C(O)NR 7 R 8 , —OR 10 , —NR 7 SO 2 R 10 , —NR 7 C═(O)R 9 , —NR 7 C(O)—OR 9 , —NR 7 OR 9 , —OCX 3 , —OCHX 2 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
L 2 is unsubstituted piperazino or unsubstituted piperidino;
L 3 is a bond;
E is an unsubstituted vinyl sulfone moiety, substituted or unsubstituted vinyl sulfonamide moiety, substituted or unsubstituted peroxide moiety, substituted or unsubstituted fluoro(C 1 -C 4 )alkylketone moiety, substituted or unsubstituted chloro(C 1 -C 4 )alkylketone moiety, substituted or unsubstituted acrylamide moiety, substituted or unsubstituted disulfide moiety, substituted or unsubstituted thiol moiety, substituted or unsubstituted phosphonate moiety, unsubstituted aldehyde moiety, substituted or unsubstituted enone moiety, substituted or unsubstituted diazomethylketone moiety, substituted or unsubstituted diazomethylamide moiety, substituted or unsubstituted cyanocyclopropyl carboxamide moiety, substituted or unsubstituted epoxide moiety, substituted or unsubstituted epoxyketone moiety, substituted or unsubstituted epoxyamide moiety, substituted or unsubstituted aryl aldehyde moiety, substituted or unsubstituted aryl dialdehyde moiety, substituted or unsubstituted dialdehyde moiety, substituted or unsubstituted nitrogen mustard moiety, substituted or unsubstituted propargyl moiety, substituted or unsubstituted propargylamide moiety,

R 7 , R 8 , R 9 , and R 10 are independently hydrogen, halogen, —CF 3 , —CN, —OH, —NH 2 , —COOH, —CONH 2 , —NO 2 , —SH, —SO 2 Cl, —SO 3 H, —SO 4 H, —SO 2 NH 2 , ——NHNH 2 , —ONH 2 , —NHC═(O)NHNH 2 , —NHC═(O) NH 2 , —NHSO 2 H, —NHC═(O)H, —NHC(O)—OH, —NHOH, —OCF 3 , —OCHF 2 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R 13 independently hydrogen, methyl, ethyl, —CN, or —NO 2 ;
m is 1 or 2; v is 1 or 2; n is an integer from 0 to 4; and
X is —Cl, —Br, —I, or —F.

2. The compound or pharmaceutically acceptable salt of claim 1 , having the formula:

3. A method of treating lung cancer in a subject in need thereof, comprising:
a. determining the presence or absence of a K-Ras mutation in a malignant or neoplastic cell isolated from the subject; and
b. if a K-Ras mutation is determined to be present in the subject, administering to the subject a therapeutically effective amount of a compound or pharmaceutically acceptable salt of claim 1 .

4. A method of treating lung cancer in a subject in need thereof, comprising:
a. determining the presence or absence of a K-Ras mutation in a malignant or neoplastic cell isolated from the subject, in connection with the prescription of an effective amount of a compound or pharmaceutically acceptable salt of claim 1 to said subject; and
b. if a K-Ras mutation is determined to be present in the subject, providing an alert to a caregiver of said subject.

5. The compound or pharmaceutically acceptable salt of claim 2 , wherein E is

6. The compound or pharmaceutically acceptable salt of claim 2 , wherein E is an unsubstituted vinyl sulfone moiety, substituted or unsubstituted vinyl sulfonamide moiety, substituted or unsubstituted peroxide moiety, substituted or unsubstituted fluoro(C 1 -C 4 )alkylketone moiety, substituted or unsubstituted chloro(C 1 -C 4 )alkylketone moiety, substituted or unsubstituted acrylamide moiety, substituted or unsubstituted disulfide moiety, substituted or unsubstituted thiol moiety, substituted or unsubstituted phosphonate moiety, unsubstituted aldehyde moiety, substituted or unsubstituted enone moiety, substituted or unsubstituted diazomethylketone moiety, substituted or unsubstituted diazomethylamide moiety, substituted or unsubstituted cyanocyclopropyl carboxamide moiety, substituted or unsubstituted epoxide moiety, substituted or unsubstituted epoxyketone moiety, substituted or unsubstituted epoxyamide moiety, substituted or unsubstituted aryl aldehyde moiety, substituted or unsubstituted aryl dialdehyde moiety, substituted or unsubstituted dialdehyde moiety, substituted or unsubstituted nitrogen mustard moiety, substituted or unsubstituted propargyl moiety, substituted or unsubstituted propargylamide moiety.

7. The compound or pharmaceutically acceptable salt of claim 2 , wherein E is an unsubstituted vinyl sulfone moiety, substituted or unsubstituted vinyl sulfonamide moiety, or a substituted or unsubstituted acrylamide moiety.

8. The compound or pharmaceutically acceptable salt of claim 2 , wherein R 3 is methyl, —Cl, —NH 2 , —I, —CCH, —CH 2 CH 2 OH, —OCH 2 CCH, —CF 3 , —OCH 3 , —OH, —CH 2 CH 3 , —NHS(O) 2 CH 3 , —CH 2 NH 2 , —Br, isoxazolyl, —NHC(O)OC(CH 3 ) 3 , p-chlorophenyl, thiophenyl, —F, pyrazolyl, —CH 2 OH, —C(O)NHCH 2 CH 2 OH, —OCH 2 CH 2 OH, —S(O) 2 NH 2 , tetrazolyl, —CHCH 3 OH, —C(O)CH 3 , —C(O)H, —OCH 3 , —C(O)OH, —C(O)OCH 3 , —C(O)NH 2 , —N(C

Assignees

• Univ California

Inventors

• Ostrem Jonathan
• Peters Ulf
• Shokat Kevan M

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• C12N9/14

  Hydrolases (3) · CPC title

• C07D495/04 Primary

  Ortho-condensed systems · CPC title